beremagene geperpavec

AXP000193.2 · Viral vector gene therapy

Platform
HSV-1 (replication-defective)
Targets
COL7A1
Originator
Krystal Biotech
Sponsor
Krystal Biotech

Names

NameTypeSource
beremagene geperpavecpreferred name, INNcurator, ncit
Vyjuvekbrandfda
B-VECcodencit
KB103codencit
beremagene geperpavec-svdtsynonymncit

Virus

Role
In vivo gene transfer
Family
Herpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Replication
non replicating
Modifications
replication-defective HSV-1 backbone (specific deletions not verified here); two copies of COL7A1 inserted
Transgenes
COL7A1
Route
topical
Source
evidence

Cross-references

NCI Thesaurus
C174623
Wikidata
Q119475442
FDA UNII
AQN7K24KQU

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2023-05-19approvedVyjuvekTreatment of wounds in adult and paediatric patients with dystrophic epidermolysis bullosa with mutation(s) in the COL7A1 genesource
EMAEU2025-04-23approvedVyjuvekTreatment of wounds in patients from birth with dystrophic epidermolysis bullosa with mutation(s) in the COL7A1 genesource
PMDAJP2025-07-24approvedVyjuvekDystrophic epidermolysis bullosasource

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06731933Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB SkinRecruitingPhase 22025-03-282027-0216Squamous Cell Carcinoma
NCT04917874A Long-term Treatment With B-VEC for Dystrophic Epidermolysis BullosaCompletedPhase 32021-05-252023-07-3147DEB - Dystrophic Epidermolysis Bullosa; Dominant Dystrophic Epidermolysis Bullosa; Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa
NCT04491604Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEBCompletedPhase 32020-08-172021-10-2931Dominant Dystrophic Epidermolysis Bullosa; Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa
NCT03536143A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB PatientsCompletedPhase 1/22018-05-062019-11-0112Dystrophic Epidermolysis Bullosa

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41025539Off-Label Use of Double-Dose Beremagene Geperpavec (B-VEC) in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: A Promising Clinical Case.Pediatric dermatology2026name in title: beremagene geperpavec
PMID 40220208Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.American journal of clinical dermatology2025cited by trial NCT04917874
PMID 40667654Efficacy and Safety of the Topical Gene Therapy Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Study of Japanese Subjects With Dystrophic Epidermolysis Bullosa.The Journal of dermatology2025name in title: beremagene geperpavec-svdt
PMID 41523446Scarring Alopecia in Localized Dystrophic Epidermolysis Bullosa: A Case Report and a Scoping Review.Cureus2025name in abstract: beremagene geperpavec
PMID 38324486Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa.The New England journal of medicine2024name in abstract: beremagene geperpavec
PMID 35347281In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.Nature medicine2022cited by trial NCT03536143
PMID 36516090Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.The New England journal of medicine2022cited by trial NCT04491604

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40158551VYJUVEK for dystrophic epidermolysis bullosa: Ethical dilemmas in access and pricing.Journal of the American Academy of Dermatology2026name in title: Vyjuvek
PMID 40892156Beremagene geperpavec (B-VEC) for infantile dystrophic epidermolysis bullosa: Benefit of early intervention.Journal of the European Academy of Dermatology and Venereology : JEADV2026name in title: beremagene geperpavec
PMID 41731282Developing CRISPR-Based Therapies for Epidermolysis Bullosa: A Comprehensive Review of Current Strategies.Drugs2026name in abstract: beremagene geperpavec
PMID 41772988Understanding the efficacy and tolerability of topical therapies for epidermolysis bullosa.Expert review of clinical pharmacology2026name in abstract: beremagene geperpavec
PMID 42578000Topical gene therapy for severe recessive dystrophic epidermolysis bullosa: clinical outcomes and multidisciplinary management in three patients treated with beremagene geperpavec (B-VEC) in Italy - a case series.Drugs in context2026name in title: beremagene geperpavec
PMID 42696401Update on Approved Therapies for Dystrophic and Junctional Epidermolysis Bullosa.Pediatric dermatology2026name in abstract: beremagene geperpavec-svdt
PMID 43018251Real-world effects of beremagene geperpavec in epidermolysis bullosa.Journal of the European Academy of Dermatology and Venereology : JEADV2026name in title: beremagene geperpavec
PMID 40464880Correction to: Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.American journal of clinical dermatology2025name in title: beremagene geperpavec-svdt
PMID 40564391Towards Extracellular Vesicles in the Treatment of Epidermolysis Bullosa.Bioengineering (Basel, Switzerland)2025name in abstract: Vyjuvek
PMID 41210910The Saudi National Policy and Protocol for Epidermolysis Bullosa.Risk management and healthcare policy2025name in abstract: beremagene geperpavec
PMID 37936299Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper.The British journal of dermatology2024name in title: beremagene geperpavec
PMID 38294784Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa.JAMA dermatology2024name in title: beremagene geperpavec
PMID 38396920Emerging Gene Therapeutics for Epidermolysis Bullosa under Development.International journal of molecular sciences2024name in abstract: beremagene geperpavec
PMID 38724041Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa.The Journal of dermatological treatment2024name in title: beremagene geperpavec-svdt
PMID 39292470Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa.JAMA dermatology2024name in title: beremagene geperpavec
PMID 39292476Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa-Reply.JAMA dermatology2024name in title: beremagene geperpavec
PMID 37432558Beremagene Geperpavec: First Approval.Drugs2023name in title: beremagene geperpavec
PMID 37595560Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB).Cell2023name in abstract: beremagene geperpavec
PMID 38004669Attenuated Replication-Competent Herpes Simplex Virus Expressing an ECM-Modifying Transgene Hyaluronan Synthase 2 of Naked Mole Rat in Oncolytic Gene Therapy.Microorganisms2023name in abstract: beremagene geperpavec
PMID 38098548Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa.Annals of medicine and surgery (2012)2023name in title: Vyjuvek
Unconfirmed matches (4)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 42648642Engineering HSV-1 for gene therapy, oncolytic immunotherapy, and neuroscience.Virologica Sinica2026name in abstract: B-VEC
PMID 38085193Current Treatment Landscape for Dystrophic Epidermolysis Bullosa: From Surgical Management to Emerging Gene Therapies and Novel Skin Grafts.The Journal of hand surgery2024name in abstract: B-VEC
PMID 38275540Management of Skin Lesions in Patients with Epidermolysis Bullosa by Topical Treatment: Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland)2024name in abstract: B-VEC
PMID 8088537A genetic and molecular characterization of the recA gene from Staphylococcus aureus.Gene1994name in abstract: KB103

Notes

Vyjuvek: topical gel of a replication-defective HSV-1 vector carrying two copies of COL7A1, for wounds of dystrophic epidermolysis bullosa. FDA approved 19 May 2023 (first redosable topical gene therapy), European Commission 23 April 2025, Japan (MHLW) September 2025. An eye-drop formulation for ocular DEB complications is the same product in a different formulation, so not a separate program.

How to cite

beremagene geperpavec (AXP000193.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000193.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.